Literature DB >> 22348565

What happens to the severity grading by objective SCORAD if we over- or underestimate disease extent or intensity in patients with atopic dermatitis?

Kam-Lun Ellis Hon1, Shuxin Susan Wang, Ting Fan Leung.   

Abstract

BACKGROUND: The objective SCORing Atopic Dermatitis (SCORAD) is a widely-used clinical score for assessing the extent, intensity, and severity of atopic dermatitis (AD).
OBJECTIVE: We evaluated the effect on the severity grading if extent or intensity was under-estimated or overestimated.
MATERIALS AND METHODS: Six-hundred and fifty-one SCORADs performed over a 40-month period were evaluated. The effect on AD severity grading of six-hundred and fifty-one SCORADs performed over a 40-month period was evaluated if disease extent or intensivity was misestimated.
RESULTS: The effect on AD grading was generally small if extent had been misestimated by 10% or 20%. In the mild grade (n=131), 40%, 62%, and 82% would have become moderate if the intensity had been underestimated by 1, 2, and 3, respectively. In the moderate grade (n=296), 13%, 27%, and 41% would have become severe if the intensity had been underestimated by 1, 2, and 3, respectively. The grading would have become mild in 16%, 31%, and 44% if the intensity had been overestimated by 1, 2, and 3, respectively. In the severe grade (n=224), 14%, 25%, and 38% would have become moderate if the intensity had been overestimated by 1, 2, and 3, respectively.
CONCLUSIONS: The effect on AD grading is generally small if extent is misestimated. A huge difference, especially if underestimated in the mild group, would occur if intensity is misestimated. Surrogate markers of disease severity could overcome or supplement shortcoming of clinical scores in AD research.
© 2012 The International Society of Dermatology.

Entities:  

Mesh:

Year:  2012        PMID: 22348565     DOI: 10.1111/j.1365-4632.2011.05004.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  3 in total

1.  Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.

Authors:  Emma Guttman-Yassky; Patrick M Brunner; Avidan U Neumann; Saakshi Khattri; Ana B Pavel; Kunal Malik; Giselle K Singer; Danielle Baum; Patricia Gilleaudeau; Mary Sullivan-Whalen; Sharon Rose; Shelbi Jim On; Xuan Li; Judilyn Fuentes-Duculan; Yeriel Estrada; Sandra Garcet; Claudia Traidl-Hoffmann; James G Krueger; Mark G Lebwohl
Journal:  J Am Acad Dermatol       Date:  2018-01-17       Impact factor: 11.527

2.  Development and initial validation of a Traditional Chinese Medicine symptom-specific outcome measure: a Zheng-related atopic dermatitis symptom questionnaire (ZRADSQ).

Authors:  Darong Wu; Chujun Huang; Xiumei Mo; Junfeng Liu; Jianxiong Cai; Chi Liu; Haili Zhu; Hongyi Li; Dacan Chen
Journal:  Health Qual Life Outcomes       Date:  2013-12-21       Impact factor: 3.186

3.  A Microbiome-Based Index for Assessing Skin Health and Treatment Effects for Atopic Dermatitis in Children.

Authors:  Zheng Sun; Shi Huang; Pengfei Zhu; Feng Yue; Helen Zhao; Ming Yang; Yueqing Niu; Gongchao Jing; Xiaoquan Su; Huiying Li; Chris Callewaert; Rob Knight; Jiquan Liu; Ed Smith; Karl Wei; Jian Xu
Journal:  mSystems       Date:  2019-08-20       Impact factor: 6.496

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.